A phase (Ph) I/II trial of the CXCR2 antagonist AZD5069 in combination with enzalutamide (ENZA) in patients (pts) with metastatic castration resistant prostate cancer (mCRPC)

ANNALS OF ONCOLOGY

ELSEVIER

1. AstraZeneca [AZD5069]
2. Prostate Cancer Foundation
3. Prostate Cancer UK
4. National Institute of Health and Research Biomedical Research Centre
5. Astellas
6. AstraZeneca